A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis (NOVA-BEAM)
An Open-Label, Multicenter, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and, pharmacodynamics (PD) of subcutaneously administered RO7845860 in participants with relapsing multiple sclerosis (RMS).
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Studer Kontakt Backup
- Navn: Reference Study ID Number BP46580 https://forpatients.roche.com/ No attachments to email below.
- Telefonnummer: 888-662-6728 (U.S. and Canada)
- E-post: global-roche-genentech-trials@gene.com
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Diagnosis of RMS (i.e., relapsing-remitting multiple sclerosis [RRMS] or a secondary progressive multiple sclerosis [SPMS] where patients still experience relapses) in accordance with the revised 2017 McDonald Criteria.
-
No relapse for 30 days prior to screening and neurologically stable with no relapse during screening.
-
Expanded Disability Status Scale (EDSS) score at screening (historical EDSS not older than 6 months may be used), from 0 to 6.5 inclusive.
-
From Part 2 onwards,
- at least two documented clinical relapses within the last 2 years prior to screening, or
- one documented clinical relapse in the year prior to screening or
- one documented clinical relapse together with signs of Magnetic Resonance Imaging (MRI) activity (any T1 Gd+ and/or new or enlarging T2 lesion) between 12 and 24 months prior to screening.
-
Documented MRI of brain with abnormalities consistent with Multiple Sclerosis (MS) at screening.
Exclusion Criteria:
-
History of primary progressive multiple sclerosis (PPMS) at screening.
-
Any of the following laboratory parameters:
- CD4 levels below lower limit of normal (LLN)
- Absolute neutrophil count (ANC) levels below LLN
- Serum immunoglobulin G (IgG) levels below LLN
- Absolute lymphocyte count < 1000 cells per microliter (μL)
- B-cell levels below LLN
-
Known presence of other neurologic disorders that may mimic MS, including but not limited to, neuromyelitis optica spectrum disease, myelin oligodendrocyte antibody associated disease, Lyme disease, untreated vitamin B-12 deficiency, cerebrovascular or spinal vascular disorders, and untreated hypothyroidism.
-
Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, dermatologic, psychiatric, allergic, renal or other major diseases that in the investigator's judgement, may affect interpretation of study results or participant safety.
-
Prior treatment with Chimeric antigen receptor (CAR) T-cell therapy, gene-therapy product, total body irradiation, bone marrow transplantation, allograft organ transplant, or hematopoietic stem cell transplant at any point.
-
Inability to complete an MRI scan (contraindications for MRI, including but not restricted to, pacemaker, cochlear implants, intracranial vascular clips, surgery within 6 weeks prior to screening coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc.) or contraindication to gadolinium administration.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Part 1: Single Ascending Dose Escalation
Participants will receive single dose of RO7845860. |
Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol. |
|
Eksperimentell: Part 2: Multiple Ascending Dose Escalation
Participants will receive multiple doses of RO7845860. |
Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol. |
|
Eksperimentell: Part 3: Dose Expansion
Participants will receive multiple doses of RO7845860. |
Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Part 1, 2 and 3: Incidence and Severity of Adverse Events (AEs)
Tidsramme: From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Part 1, 2 and 3: Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsramme: From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Part 1, 2 and 3: Serum Concentration of RO7845860
Tidsramme: At prespecified timepoints from Baseline up to approximately Week 96
|
At prespecified timepoints from Baseline up to approximately Week 96
|
|
Part 1, 2 and 3: Percentage of Participants Achieving B-Cell Levels Below the Lower Limit of Quantitation in Blood as per Employed High-Sensitive Flow Cytometry Assay
Tidsramme: From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Part 1, 2 and 3: B-Cell Levels Over Time in Blood
Tidsramme: From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Parts 1, 2 and 3: Median Time to Repletion of B-Cells in Blood to the Lower Limit of Normal or to the Detection Limit of the B-cell Assays
Tidsramme: From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Parts 2 and 3: Change From Baseline in B-Cell Levels in Cerebrospinal Fluid (CSF)
Tidsramme: From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Parts 1, 2 and 3: Prevalence and Incidence of Anti-drug Antibodies (ADAs) to RO7845860
Tidsramme: From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Clinical Trials, Hoffmann-La Roche
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
Andre studie-ID-numre
- BP46580
- 2026-526353-34-00 (Annen identifikator: EU CT Number)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .